It’s official, Pfizer’s COVID-19 vaccine has been renamed Comirnaty and it will begin to be commercialized in the United States. But, what is the reason for the name change?

In the strange world of drug branding a strange name can be a success, will this be the case of the Pfizer COVID-19 vaccine? Comirnaty, it is not the only vaccine against COVID-19 with a strange name.

Previously, We met Spikevax, the European brand of Modern vaccine that owes its name to the Brand Institute. Spikevax refers directly to the pointed structure of the COVID-19 virus and the word vaccines is represented in the “vax”.

DO NOT STOP READING: GM’s Bolt EUV arrives in Mexico Does it go to you for you with Tesla Model Y?

On the other hand, in the market Vaxzevria is also marketed, which is the commercial name under which the vaccine is sold AstraZeneca in Europe, this name is not interesting to explain: Spike + Vax (vaccine).

Now, with official approval from the Food and Drug Administration, the vaccine COVID-19 mRNA from Pfizer / BioNTech (which is the proper name for laboratory) can now be marketed as Comirnaty in the United States.

Apparently the name change is due to a marketing strategy to commercialize Pfizer’s vaccine. Name Comirnaty is an acronym for several words: community, immunity, COVID-19 and mRNA, depending on the brand.

OFFICIAL: Pfizer vaccine changes name, will now be called 'Comirnaty'

The new name was created for Pfizer-BioNTech by the Brand Institute, which is known as the number one name company in the world and that as we said I also created the Spikevax brand for the Moderna vaccine, and although the result is not the easiest thing to pronounce or remember, at least it is shorter than the laboratory names.

With the name change Corminaty, the brand seeks a second wind to compete in the United States market with Vaxzevria and Spikevax. It is interesting to think that a name is commercial is the most important thing for those who need to acquire a vaccine. What are the fundamental reasons for choosing a vaccine?